Markman hearing

Fish & Richardson Named Law360 2020 IP Practice Group of the Year

Retrieved on: 
Tuesday, December 1, 2020

BOSTON, Dec. 1, 2020 /PRNewswire/ -- Fish & Richardson has been named a 2020 IP Practice Group of the Year by Law360 forits high-profile wins in federal courts across the United States, at the Federal Circuit, at the International Trade Commission (ITC), and before the Patent Trial and Appeal Board (PTAB).

Key Points: 
  • BOSTON, Dec. 1, 2020 /PRNewswire/ -- Fish & Richardson has been named a 2020 IP Practice Group of the Year by Law360 forits high-profile wins in federal courts across the United States, at the Federal Circuit, at the International Trade Commission (ITC), and before the Patent Trial and Appeal Board (PTAB).
  • Fish was one of only six firms nationwide singled out by Law360 for this prestigious award.
  • Now,our lawyers are busy doing remote depositions and Markman hearings, remote Federal Circuit appeals, and remote trials," said Kurt Glitzenstein , Litigation Practice Group Leader at Fish.
  • Fish & Richardson, the premier global intellectual property law firm, is trusted by the world's most innovative and influential companies.

Lipocine Announces Outcome of Markman Hearing in Patent Infringement Suit Against Clarus

Retrieved on: 
Thursday, March 26, 2020

The purpose of a Markman Hearing is to determine the precise meaning of words from patent claims that are in dispute in a patent infringement lawsuit.

Key Points: 
  • The purpose of a Markman Hearing is to determine the precise meaning of words from patent claims that are in dispute in a patent infringement lawsuit.
  • No ultimate determination of infringement or validity of the patents has been determined at this point.
  • The Markman Hearing Order, issued by the United States District Court of Delaware, has been posted on Lipocine's website at: https://ir.lipocine.com/presentations .
  • Lipocine has a pending suit against Clarus in the United States District Court of Delaware alleging that Clarus's JATENZO product infringes Lipocine's U.S. patents: 9,034,858; 9,205,057; 9,480,690; and 9,757,390.